Депрескрайбинг против полипрагмазии: возможности метода


DOI: https://dx.doi.org/10.18565/pharmateca.2019.9.26-34

М.В. Леонова

Ассоциации клинических фармакологов России, Москва, Россия

Представлен научный обзор по методологии депрескрайбинга у пожилых пациентов с полипрагмазией. Депрескрайбинг предполагает проведение отмены или уменьшение дозировок лекарственных средств (ЛС), которые с длительностью лечения пожилых пациентов стали неподходящими или потеряли обоснование к применению. Депрескрайбинг – это не отказ от назначения эффективного ЛС, а позитивное пациенториентированное вмешательство, которое требует совместного принятия решений, информированного согласия пациента и тщательного мониторинга эффектов на основе принципов качественного назначения ЛС. Депрескрайбинг направлен на уменьшение частоты побочных эффектов, связанных с использованием ЛС, на улучшение функционального состояния и предупреждение преждевременной смертности. Кроме того, проведение депрескрайбинга позволяет уменьшить лекарственную нагрузку на пациента и улучшить приверженность фармакотерапии. В обзор включены данные доказательной медицины, включая мета-анализы клинических и наблюдательных когортных исследований, в т.ч. по конкретным фармакологическим классам ЛС – психотропным, ингибиторам протонной помпы, антигипертензивным, статинам, а также данные по депрескрайбингу в госпитальном секторе. Во многих случаях проведение депрескрайбинга позволяет улучшить состояние и качество жизни пациентов, а также исходы. Методология депрескрайбинга получила широкое обоснование, подготовлены руководства и алгоритмы, проводится конференция.


Для цитирования: Леонова М.В. Депрескрайбинг против полипрагмазии: возможности метода. Фарматека. 2019;26(9):26–34. DOI: https://dx.doi.org/10.18565/pharmateca.2019.9.26-34 


Литература


1. Thompson W., Farrell B. Deprescribing: What Is It and What Does the Evidence Tell Us? Can J Hosp Pharm. 2013;66(3):201–2.

2. Woodward M. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003;33:323–28. DOI: 10.1002/jppr2003334323.

3. Page A.T., Potter K., Clifford R., Etherton-Beer C.Deprescribing in older people. Maturitas. 2016;91:115–34. Doi: 10.1016/j.maturitas.2016.06.006.

4. Shah B.M., Hajjar E.R. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28(2):173–86. Doi 10.1016/j.cger.2012.01.002.

5. Gnjidic D., Hilmer S.N., Blyth F.M., et al. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse out-comes, J Clin Epidemiol. 2012;65: 989–95. Doi: 10.1016/j.jclinepi.2012.02.018.

6. Kennedy-Martin T., Curtis S., Faries D., et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Tri-als. 2015;16:495. Doi: 10.1186/s13063-015-1023–24.

7. Rockwood K., Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol Series A: Biol Sci Med Sci. 2007;62:722–27. Doi: 10.1093/gerona/62.7.722.

8. Poudel A., Hubbard R.E., Nissen L., Mitchell C.Frailty: A key indicator to minimize inappro-priate medication in older people. QJM. 2013;106(10):969–75. Doi 10.1093/qjmed/hct146.

9. Hilmer S.N., McLachlan A.J., Le Couteur D.G. Clinical pharmacology in the geriatric patient. Fundam. Clin Pharmacol. 2007;21:217–30. Doi: 10.1111/j.1472-8206.2007.00473.x.

10. Reeve E., Gnjidic D., Long J., Hilmer S. A systematic review of the emerging definition of ’deprescribing’ with network analysis: Implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80:1254–68. DOI: 10.1111/bcp.12732.

11. Iyer S., Naganathan V., McLachlan A.J., Le Couteur D.G. Medication withdrawal trials in people aged 65 years and older. Drugs Aging. 2008;25(12):1021–31. Doi: 10.2165/0002512-200825120-00004.

12. Page A.T., Clifford R.M., Potter K., et al. The feasibility and the effect of deprescribing in older adults on mortality and health: a systematic review. Br J Clin Pharmacol. 2016;82(3):583–623. Doi 10.1111/bcp.12975.

13. Sateia M.J., Buysse D.J., Krystal A.D., et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–49. Doi: 10.5664/jcsm.6470.

14. Parr J.M., Kavanagh D.J., Cahill L., et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104(1):13–24. Doi: 10.1111/j.1360-0443.2008.02364.x.

15. Gould R.L., Coulson M.C., Patel N., et al. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98–107. Doi 10.1192/bjp.bp.113.126003.

16. Voshaar R.C., Couvée J.E., van Balkom A.J., et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213–20. Doi: 10.1192/bjp.189.3.213.

17. Pollmann A.S., Murphy A.L., Bergman J.C., Gardner D.M. Deprescribing benzodiazepines and Zdrugs in community-dwelling adults: a scoping review. BMC. Pharmacol Toxicol. 2015;16(1):19. Doi: 10.1186/s40360-015-0019-8.

18. Declercq T., Petrovic M., Azermai M., et al. Withdrawal versus continuation of chronic anti-psychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;28(3):CD007726. Doi: 10.1002/14651858.

19. Van Leeuwen E., Petrovic M., van Driel M.L., et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:CD007726. Doi: 10.1002/14651858.CD007726.pub3.

20. Farrell B., Pottie K., Thompson W., et al. Deprescribing proton pump inhibitors: еvidence-based clinical practice guideline. Can Fam Physician. 2017;63:354–64.

21. Boghossian T.A., Rashid F.J., Welch V., et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2015;16(3):CD011969. Doi 10.1002/14651858.CD011969.pub2.

22. Haastrup P., Paulsen M., Begtrup L., et al. Strategies for discontinuation of proton pump in-hibitors: a systematic review. Fam Pract. 2014;31(6):625–30. Doi 10.1093/fampra/cmu050.

23. Wilsdon T.D., Hendrix I., Thynne T.R., Mangoni A.A.Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults. Drugs Aging. 2017;34(4):265–87. Doi 10.1007/s40266-017-0442-1.

24. Ravindrarajah R., Hazra N.C., Hamada S., et al. Systolic Blood Pressure Trajectory, Frailty, and All-Cause Mortality >80 Years of Age: Cohort Study Using Electronic Health Records. Cir-culation. 2017;135(24):2357–68. Doi: 10.1161/CIRCULATIONAHA.116.026687.

25. Douros A., Tölle M., Ebert N., et al. Control of blood pressure and risk of mortality in a co-hort of older adults: the Berlin Initiative Study. Eur Heart J. 2019;0:1–8. Doi: 10.1093/eurheartj/ehz071.

26. Delgado J., Bowman K., Ble A., Masoli J, et al. Blood Pressure Trajectories in the 20 Years Before Death. JAMA. Intern. Med. 2018;178(1):93–9. doi: 10.1001/jamainternmed.2017.7023.

27. Moonen J.E.F., Foster-Dingley J.C., Ce Ruijter W., et al. Effect of discontinuation of antihy-pertensive treatment in elderly people on cognitive functioning-the DANTE Study Leiden: a randomized clinical trial. JAMA. Intern Med. 2015;175:1622–30. Doi: 10.1001/jamainternmed.2015.4103.

28. Gulla C., Flo E., Kjome R.L.S., Husebo B.S. Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure. J Geriatr Cardiol. 2018;15(4):275–83. DOI: 10.11909/j.issn.1671-5411.2018.04.011.

29. Van der Wardt V., Harrisonb J.K., Welshc T., et al. Withdrawal of antihypertensive medica-tion: a systematic review. J Hypertens. 2017;35:1742–49. DOI: 10.1097/HJH.0000000000001405.

30. Chou R., Dana T., Blazina I., et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–24. Doi: 10.1001/jama.2015.15629.

31. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lan-cet. 2019;393:407–15. Doi: 10.1016/S0140-6736(18)31942-1.

32. Savarese G., Gotto A.M. Jr, Paolillo S., et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–99. Doi: 10.1016/j.jacc.2013.07.069.

33. Mortensen M.B., Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85–94. Doi: 10.1016/j.jacc.2017.10.080.

34. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs

35. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42. Doi: 10.1016/S0140-6736(09)61965-6.

36. Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123–30. Doi: 10.1016/j.amjcard.2012.12.037.

37. Sever P.S., Chang C.L., Gupta A.K., et al.; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. 2011;32(20):2525–32. Doi: 10.1093/eurheartj/ehr333.

38. Westaway, K.P., Frank O.R., Husband A.J., et al. Safe use of statin in elderly people. J Pharm Pract Res. 2014;44(3):138–42. Doi: 10.1002/jppr.1022.

39. Holmes H.M., Todd А. Evidence-based deprescribing of statins in patients with advanced illness. JAMA. Intern Med. 2015;175(5):701–2. Doi: 10.1001/jamainternmed.2015.0328.

40. Kutner J.S., Blatchford P.J., Taylor D.H.J., et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA. Intern Med. 2015;175(5):691–700. Doi: 10.1001/jamainternmed.2015.0289.

41. Tjia J., Kutner J.S., Ritchie C.S., et al. Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. J Palliat Med. 2017;20(10):1098–103. Doi: 10.1089/jpm.2016.0489.

42. Nishtala P.S., Gnjidic D., Chyou T., Hilmer S.N. Discontinuation of statins in a population of older New Zealanders with limited life expectancy. Intern Med J. 2016;46(4):493–96.

43. Christensen M., Lundh A. Medication review in hospitalized patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2016;2:Cd008986. Doi: 10.1111/imj.13024.

44. Thillainadesan J., Gnjidic D., Green S., Hilmer S.N. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of random-ised trials. Drugs Aging. 2018;35(4):303–19. Doi: 10.1007/s40266-018-0536-4.

45. Scott I.A., Hilmer S.N., Reeve E., et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA. Intern Med. 2015;175(5):827–34. Doi: 10.1001/jamainternmed.2015.0324.

46. Garfinkel D., Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170(18):1648–54. Doi: 10.1001/archinternmed.2010.355.

47. Pottie K., Thompson W., Davies S., et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339–51.

48. Bjerre L.M., Farrell B., Hogel M., et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27.

49. Farrell B., Pottie K., Thompson W., et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354–64.

50. Farrell B., Conklin J., Dolovich L., et al. Deprescribing guidelines: An international sympo-sium on development, implementation, research and health professional education. Res Social Adm Pharm. 2018;pii: S1551–7411(18)30744-7. Doi: 10.1016/j.sapharm.2018.08.013.

51. Chou J., Tong M., Brandt N.J. Combating polypharmacy through deprescribing potentially inappropriate medications. J Gerontol Nurs. 2019;45(1):9–15. Doi: 10.3928/00989134-20190102-01.


Об авторах / Для корреспонденции


Автор для связи: М.В. Леонова, д.м.н., профессор, член-корр. РАЕН, клинический фармаколог, член Межрегиональной общественной организации «Ассоциация клинических фармакологов России», Москва, Россия; e-mail: anti23@mail.ru; ORCID: https://orcid.org/0000-0001-8228-1114, Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=7004151126 
Адрес: 117997, Россия, Москва, ул. Островитянова, 1


Похожие статьи


Бионика Медиа